Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Apr;50(4):1531-4.
doi: 10.1128/AAC.50.4.1531-1534.2006.

Plasmodium falciparum in vitro susceptibility to antimalarial drugs in Casamance (southwestern Senegal) during the first 5 years of routine use of artesunate-amodiaquine

P Agnamey  1 , P Brasseur, P Eldin de Pecoulas, Michel Vaillant, P Olliaro
Affiliations

Plasmodium falciparum in vitro susceptibility to antimalarial drugs in Casamance (southwestern Senegal) during the first 5 years of routine use of artesunate-amodiaquine

P Agnamey et al. Antimicrob Agents Chemother. 2006 Apr.

Abstract

We have monitored the in vitro sensitivities of Plasmodium falciparum isolates predeployment and during the deployment of artesunate plus amodiaquine treatment in Mlomp, Casamance (southwestern Senegal) during 2000 to 2004. Parasites remained susceptible to both drugs. Chloroquine resistance levels were high but stable. Quinine continues to be effective.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Box plots of log-transformed IC50s (in nM) for chloroquine (a), quinine (b), monodesethyl amodiaquine (c), and artemisinin (d) by year (1997 and 2000 to 2004). The percentages of isolates above the cutoff value for in vitro resistance (dotted horizontal lines) are displayed for each drug. The top (or the base) of the whisker corresponds to the largest (or the lowest) observed value within the 1.5× interquartile range (IQ) from the 75th (or 25th) percentile. □, mean; ⋄, values outside 1.5× IQ.
See this image and copyright information in PMC

References

    1. Adjuik, M., P. Agnamey, A. Babiker, S. Borrmann, P. Brasseur, F. Cobelens, S. Diallo, J. F. Faucher, P. Garner, S. Gikunda, P. G. Kremsner, S. Krishna, B. Lell, M. Loolpapit, P. B. Matsiegui, M. A. Missinou, J. Mwanza, F. Ntoumi, P. Olliaro, P. Osimbo, P. Rezbach, M. Cisse, E. Some, and W. R. J. Taylor. 2002. Artesunate-amodiaquine versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 359:1365-1372. - PubMed
    1. Agnamey, P., P. Brasseur, M. Cissé, O. Gaye, J. Dumoulin, J. Rigal, W. R. J. Taylor, and P. Olliaro. 2005. Economic evaluation of a policy change from single-agent treatment for suspected malaria to artesunate-amodiaquine for microscopically confirmed uncomplicated falciparum malaria in the Oussouye district of southwestern Senegal. Trop. Med. Int. Health 10:926-933. - PubMed
    1. Brasseur, P., P. Druilhe, J. Kouamouo, O. Brandicourt, M. Danis, and S. R. Moyou. 1986. High level of sensitivity to choloroquine of 72 Plasmodium falciparum isolates from southern Cameroon in January 1985. Am. J. Trop. Med. Hyg. 35:711-716. - PubMed
    1. Brasseur, P., R. Guiguemde, S. Diallo, V. Guiyedi, M. Kombila, P. Ringwald, and P. Olliaro. 1999. Amodiaquine remains effective for treating uncomplicated malaria in West and Central Africa. Trans. R. Soc. Trop. Med. Hyg. 86:609-612. - PubMed
    1. Churchill, F. C., L. C. Patchen, C. C. Campbell, I. K. Schwartz, P. Nguyen-Dinh, and C. M. Dickinson. 1985. Amodiaquine as pro-drug: the importance of metabolite(s) in the antimalarial effect of amodiaquine in humans. Life Sci. 36:53-62. - PubMed

Publication types

LinkOut - more resources